echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > GIE: RF ablation can significantly reduce the further development of low-level atypical growth of Barrett's esothra.

    GIE: RF ablation can significantly reduce the further development of low-level atypical growth of Barrett's esothra.

    • Last Update: 2020-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Barrett esophagealitis (BE) is a precancer lesions of esophageal adenocarcinoma, which is on the rise, and patients gradually develop from non-hyperpluric endoscopic epithelitis (IM) to low-level atypical hyperplocysis (LGD), highly atypical hyperpluration (HGD) and eventually inflamed cancer.
    current international guidelines recommend endoscopic therapy with HGD or early BE endoscopic excision (ER) or radio frequency ablation (RFA).
    the purpose of this study was to explore radio frequency ablation (RFA) for reducing Barrett's esopathy researchers by randomly assigning BE patients diagnosed with LGD to RFA or monitoring conservative treatment groups.
    observational outcome was the rate at which BE patients progressed to highly atypical growth (HGD)/cancer.
    136 patients were randomly assigned to the RFA (n s 68) or monitoring (n s 68) group in this study.
    study, 15 patients monitored were analyzed for the risk of RFA cancer based on their preferences and findings.
    study showed that the medium follow-up time from random grouping to the last endoscopy was 73 months.
    1 patient (1.5%) in the RFA group was finally diagnosed with HGD/cancer, and 23 (33.8%) in the monitoring group were diagnosed with HGD/cancer (P s .0001), thus reducing the absolute risk by 32.4% (95% confidence interval (CI), 22.4%-44.2%).
    83 patients treated with RFA (90%; 95% CI, 82.1%-95.0%) achieved BE's complete removal and atypical growth.
    7 out of 75 patients (9%; 95% CI, 4.6%-18.0%) relapsed.
    study confirmed that BE patients with LGD significantly reduced the risk of malignant progressity after RFA.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.